Hodges Capital Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$10.3M Sell
132,071
-2,625
-2% -$179K 0.68% 51
2026
Q1
$8.71M Buy
134,696
+21,342
+19% +$1.5M 0.72% 50
2025
Q4
$7.63M Sell
113,354
-6,852
-6% -$461K 0.66% 51
2025
Q3
$8.82M Sell
120,206
-31,950
-21% -$2.12M 0.75% 41
2025
Q2
$7.92M Sell
152,156
-41,409
-21% -$2.36M 0.76% 46
2025
Q1
$12.4M Sell
193,565
-139,389
-42% -$8.1M 1.23% 20
2024
Q4
$15.9M Buy
332,954
+12,410
+4% +$636K 0.95% 32
2024
Q3
$18.3M Sell
320,544
-18,312
-5% -$1.05M 1.18% 22
2024
Q2
$17.7M Buy
338,856
+21,811
+7% +$957K 1.19% 21
2024
Q1
$12.9M Buy
317,045
+120,580
+61% +$4.52M 0.82% 35
2023
Q4
$7.26M Buy
+196,465
New +$7.4M 0.39% 74

Other funds holding HALO

Hodges Capital Management's HALO Position: Q2 2026 in Review

Hodges Capital Management reduced its Halozyme (HALO) stake by 1.9% in Q2 2026, selling an estimated $179K and leaving 132,071 shares worth $10.3M. The position accounts for 0.68% of the portfolio, ranked #51.

Hodges Capital Management first reported a position in HALO in Q4 2023 and has held it in 11 quarters since. The position peaked at $18.3M in Q3 2024. 342 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Hodges Capital Management held 132,071 shares of Halozyme worth $10.3M as of Q2 2026.
  • Hodges Capital Management sold 2,625 Halozyme shares in Q2 2026, an estimated $179K.
  • Halozyme made up 0.68% of Hodges Capital Management's portfolio in Q2 2026, its #51 holding.
  • Hodges Capital Management first reported a position in Halozyme in Q4 2023 and has held it in 11 quarters since.
  • Hodges Capital Management's Halozyme position peaked at $18.3M in Q3 2024.
  • 342 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Hodges Capital Management's 13F filing for Q2 2026, filed 3 Aug 2026.